Natural Product (NP) Details
| General Information of the NP (ID: NP3152) | |||||
|---|---|---|---|---|---|
| Name |
Milrinone
|
||||
| Synonyms |
milrinone; 78415-72-2; Primacor; Milrinona; Milrinonum; 6-methyl-2-oxo-5-pyridin-4-yl-1H-pyridine-3-carbonitrile; WIN 47203; 2-methyl-6-oxo-1,6-dihydro-[3,4'-bipyridine]-5-carbonitrile; UNII-JU9YAX04C7; 3-Cyano-6-methyl-5-(4-pyridyl)-2-pyridone; MFCD00133539; 2-methyl-6-oxo-1,6-dihydro-3,4'-bipyridine-5-carbonitrile; 1,6-Dihydro-2-methyl-6-oxo(3,4'-bipyridine)-5-carbonitrile; 6-methyl-2-oxo-5-(pyridin-4-yl)-1,2-dihydropyridine-3-carbonitrile; Win-47203-2; Corotrope; 1,6-Dihydro-2-methyl-6-oxo-(3,4'-bipyridine)-5-carbonitrile; CHEMBL189; JU9YAX04C7; CHEBI:50693; Milrinone, 97%; Milrinonum [Latin]; NCGC00015675-08; NCGC00164390-01; Milrinona [Spanish]; WIN 47,203-2; [3,4'-Bipyridine]-5-carbonitrile, 1,6-dihydro-2-methyl-6-oxo-; CAS-78415-72-2; (3,4'-BIPYRIDINE)-5-CARBONITRILE, 1,6-DIHYDRO-2-METHYL-6-OXO-; DSSTox_CID_3324; DSSTox_RID_76978; DSSTox_GSID_23324; 1,6-Dihydro-2-methyl-6-oxo-[3,4'-bipyridine]-5-carbonitrile; 2-Methyl-6-oxo-1,6-dihydro-3,4'-bipyridine-5-carbonitrile (Milrinone); YM 018; SMR000058475; Milrila (TN); Milrinone(Primacor); WIN 47203-2; CCRIS 3795; SR-01000075524; EINECS 278-903-6; BRN 3546821; Milrinone [USAN:USP:INN:BAN]; 6-Methyl-5-(4-pyridyl)-2-pyridone-3-carbonitrile; Milrinone (Primacor); Tocris-1504; 111GE027; (3,4'-Bipyridine)-5-carbonitrile, 6-dihydro-2-methyl-6-oxo-; 1,2-DIHYDRO-6-METHYL-2-OXO-5-(4-PYRIDINYL)NICOTINONITRILE; Prestwick0_001065; Prestwick1_001065; Prestwick2_001065; Prestwick3_001065; Lopac-M-4659; M1663; M 4659; (non-labelled)Milrinone-d3; Milrinone (JAN/USP/INN); Lopac0_000737; SCHEMBL36947; BSPBio_001050; MLS000028818; MLS001424052; MLS006011946; BIDD:GT0197; SPBio_002965; BPBio1_001156; GTPL5225; SCHEMBL8309385; DTXSID5023324; BDBM15296; AOB5617; HMS1571E12; HMS2051L10; HMS2090J14; HMS2098E12; HMS2234A23; HMS3262C16; HMS3267P12; HMS3370H18; HMS3393L10; HMS3656G06; HMS3715E12; HMS3742G09; Pharmakon1600-01505489; AMY40564; BCP02956; ZINC9224016; Tox21_112113; Tox21_400069; Tox21_500737; ANW-42920; CM0151; Milrinone, >=97% (TLC), powder; NSC760072; s2484; SBB055743; Milrinone - CAS 78415-72-2; AKOS015836135; Tox21_112113_1; AC-4730; BCP9000926; CCG-101020; CCG-204822; CS-1367; DB00235; KS-1440; LP00737; MCULE-8377851655; NC00270; NSC 760072; NSC-760072; SDCCGSBI-0050715.P002; NCGC00015675-01; NCGC00015675-02; NCGC00015675-03; NCGC00015675-04; NCGC00015675-05; NCGC00015675-06; NCGC00015675-07; NCGC00015675-09; NCGC00015675-11; NCGC00015675-24; NCGC00025189-01; NCGC00025189-02; NCGC00025189-03; NCGC00261422-01; HY-14252; SMR004703527; SY028050; BCP0726000256; AB0010910; AB00514027; EU-0100737; FT-0630859; SW197308-3; C07224; D00417; AB00514027-02; AB00514027-03; AB00514027_04; AB00514027_05; AB00597139-08; 415M722; A839417; Q847399; SR-01000075524-1; SR-01000075524-3; SR-01000075524-4; SR-01000075524-6; W-104284; BRD-K67080878-001-05-5; Z1522568219; 6-methyl-2-oxo-5-(4-pyridyl)hydropyridine-3-carbonitrile; 1,2-dihydro-6-methyl-2-oxo-5-(4 -pyridinyl)nicotinonitrile; 2-Methyl-6-oxo-1,6-dihydro-[3,4']bipyridinyl-5-carbonitrile; Milrinone, United States Pharmacopeia (USP) Reference Standard; 1,2-DIHYDRO-6-METHYL-2-OXO-5-(4-PYRIDINYL)-NICOTINONITRILE; 6-methyl-2-oxidanylidene-5-pyridin-4-yl-1H-pyridine-3-carbonitrile; 1,6-Dihydro-2-methyl-6-oxo-(3,4 inverted exclamation mark -bipyridine)-5-carbonitrile
Click to Show/Hide
|
||||
| Species Origin | Homo sapiens ... | Click to Show/Hide | |||
| Homo sapiens | |||||
| Disease | Heart failure [ICD-11: BD10] | Approved | [1] | ||
| Structure |
|
Click to Download Mol2D MOL |
|||
| ADMET Property |
Absporption
Caco-2 Permeability
-5.013
MDCK Permeability
-4.753
PAMPA
- - -
HIA
- - -
Distribution
VDss
0.274
PPB
37.3%
BBB
+++
Metabolism
CYP1A2 inhibitor
- - -
CYP1A2 substrate
+++
CYP2C19 inhibitor
- - -
CYP2C19 substrate
+++
CYP2C9 inhibitor
- - -
CYP2C9 substrate
- -
CYP2D6 inhibitor
- - -
CYP2D6 substrate
- -
CYP3A4 inhibitor
- - -
CYP3A4 substrate
+++
CYP2B6 inhibitor
- - -
CYP2B6 substrate
- - -
CYP2C8 inhibitor
- - -
HLM Stability
- - -
Excretion
CLplasma
11.454
T1/2
1.727
Toxicity
DILI
++
Rat Oral Acute Toxicity
++
FDAMDD
-
Respiratory
++
Human Hepatotoxicity
+
Ototoxicity
-
Drug-induced Nephrotoxicity
- -
Drug-induced Neurotoxicity
++
Hematotoxicity
- -
Genotoxicity
+++
Tips: 1. For the classification endpoints, the prediction probability values are transformed into six symbols: 0-0.1 (- - -), 0.1-0.3 (- -), 0.3-0.5 (-), 0.5-0.7 (+), 0.7-0.9 (++), and 0.9-1.0 (+++).
2. Additionally, the corresponding relationships of the three labels are as follows: excellent; medium; poor.
Click to Show/Hide
|
||||
| Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product | |||||
| Formula |
C12H9N3O
|
||||
| PubChem CID | |||||
| Canonical SMILES |
CC1=C(C=C(C(=O)N1)C#N)C2=CC=NC=C2
|
||||
| InChI |
1S/C12H9N3O/c1-8-11(9-2-4-14-5-3-9)6-10(7-13)12(16)15-8/h2-6H,1H3,(H,15,16)
|
||||
| InChIKey |
PZRHRDRVRGEVNW-UHFFFAOYSA-N
|
||||
| CAS Number |
CAS 78415-72-2
|
||||
| ChEBI ID | |||||
| Herb ID | |||||
| TTD Drug ID | |||||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. A List of Drug(s) Whose Efficacy can be Enhanced by This NP | ||||||
| Sildenafil | Erectile dysfunction | Click to Show/Hide the Molecular Data of This Drug | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [2] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| In-vivo Model | Male Wistar rat hearts were isolated using an in vitro Langendorff system. | |||||
| Experimental
Result(s) |
Treatment with sildenafil and milrinone in lower concentrations had an equally strong cardioprotective effect regarding infarct size reduction compared with the administration of "protective" concentrations. | |||||
| Target and Pathway | ||||
|---|---|---|---|---|
| Target(s) | Phosphodiesterase 3 (PDE3) | Molecule Info | [3] | |